Scancell Holdings Share News (SCLP)
SCLP Share
SCLP Share
SCLP Share
SCLP Share
SCLP
SCLP Share
SCLP Level 2
SCLP Live
SCLP Broker
SCLP Directors
SCLP Financial
SCLP
SCLP Short
SCLP
Last checked at -
(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.
3 Feb 20 14:20Scancell Gets US FDA Approval For SCIB1 Drug Application
3 Feb 20 10:44Scancell Interim Loss Narrows, Progresses On Product Pipeline
31 Jan 20 11:12Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment
20 Jan 20 12:04DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares
18 Dec 19 16:29(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.
16 Dec 19 13:30Scancell Shares Jump As It Secures First Deal In China For AvidiMab
16 Dec 19 09:21Oxford Technology VCTs Report Mixed Third-Quarter Performances
12 Dec 19 14:23Scancell To Receive New European Patent For Moditope Product
20 Nov 19 10:01Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive
23 Oct 19 10:48Friday 6 SeptemberMySale Group (re share placing)Berkeley GroupGreene 9 African Oil & 10 11 Design
5 Sep 19 16:03(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.
4 Sep 19 08:58(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.
20 Aug 19 10:59(Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said its loss widened on higher development costs, while it is making strong progress on advancing its the 12 months to the of
20 Aug 19 10:59(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.
19 Aug 19 09:33
Last checked at